Expression of the histocompatibility glycoprotein HLA-DR in neurological disease
Identifieur interne : 004C23 ( Main/Exploration ); précédent : 004C22; suivant : 004C24Expression of the histocompatibility glycoprotein HLA-DR in neurological disease
Auteurs : P. L. Mcgeer [Canada] ; S. Itagaki [Canada] ; E. G. Mcgeer [Canada]Source :
- Acta Neuropathologica [ 0001-6322 ] ; 1988-11-01.
English descriptors
- KwdEn :
- Alzheimer Disease (immunology), Alzheimer Disease (pathology), Brain Diseases (immunology), Brain Diseases (pathology), HLA-DR Antigens (metabolism), Humans, Huntington Disease (immunology), Huntington Disease (pathology), Immunohistochemistry, Macrophages (immunology), Macrophages (pathology), Neuroglia (immunology), Neuroglia (pathology), Parkinson Disease (immunology), Parkinson Disease (pathology).
- MESH :
- chemical , metabolism : HLA-DR Antigens.
- immunology : Alzheimer Disease, Brain Diseases, Huntington Disease, Macrophages, Neuroglia, Parkinson Disease.
- pathology : Alzheimer Disease, Brain Diseases, Huntington Disease, Macrophages, Neuroglia, Parkinson Disease.
- Humans, Immunohistochemistry.
Abstract
Summary: Reactive microglia or macrophages expressing the histocompatibility glycoprotein HLA-DR were detected in many neurological diseases including Alzheimer's, Parkinson's, Pick's and Huntington's diseases, parkinsonism-dementia of Guam, amyotrophic lateral sclerosis, Shy-Drager syndrome, multiple sclerosis and AIDS encephalopathy. Reactive astrocytes, also present in these conditions, were established as a population distinct from the HLA-DR positive microglia by double immunostaining for glial fibrillary acidic protein and HLA-DR. A distinctive pattern of HLA-DR positive cells was seen in each disease entity. Areas known to contain pathology always stained positively, and, in several cases, reactive microglia appeared in areas that would otherwise not have been suspected of being involved in the pathological process. HLA-DR staining, which outlines the surface membranes of positive cells, was so strong that lesioned areas could frequently be identified in sections with the naked eye. In adjacent sections stained with H&E or sections destained of HLA-DR and then restained with H&E, gliosis was often hard to identify except on close microscopic inspection. The results suggest that HLA-DR staining may be a valuable addition to standard neuropathological methods and might be useful in investigating diseases where pathology has not yet been identified.
Url:
DOI: 10.1007/BF00689592
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000430
- to stream Istex, to step Curation: 000430
- to stream Istex, to step Checkpoint: 002290
- to stream Main, to step Merge: 005607
- to stream PubMed, to step Corpus: 001C75
- to stream PubMed, to step Curation: 001C75
- to stream PubMed, to step Checkpoint: 001C75
- to stream Ncbi, to step Merge: 002298
- to stream Ncbi, to step Curation: 002298
- to stream Ncbi, to step Checkpoint: 002298
- to stream Main, to step Merge: 005526
- to stream Main, to step Curation: 004C23
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Expression of the histocompatibility glycoprotein HLA-DR in neurological disease</title><author><name sortKey="Mcgeer, P L" sort="Mcgeer, P L" uniqKey="Mcgeer P" first="P. L." last="Mcgeer">P. L. Mcgeer</name></author><author><name sortKey="Itagaki, S" sort="Itagaki, S" uniqKey="Itagaki S" first="S." last="Itagaki">S. Itagaki</name></author><author><name sortKey="Mcgeer, E G" sort="Mcgeer, E G" uniqKey="Mcgeer E" first="E. G." last="Mcgeer">E. G. Mcgeer</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:253F431DB3D03242FFD77C4693FA3EC8BAA74E22</idno><date when="1988" year="1988">1988</date><idno type="doi">10.1007/BF00689592</idno><idno type="url">https://api-v5.istex.fr/document/253F431DB3D03242FFD77C4693FA3EC8BAA74E22/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000430</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000430</idno><idno type="wicri:Area/Istex/Curation">000430</idno><idno type="wicri:Area/Istex/Checkpoint">002290</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002290</idno><idno type="wicri:doubleKey">0001-6322:1988:Mcgeer P:expression:of:the</idno><idno type="wicri:Area/Main/Merge">005607</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:2974227</idno><idno type="wicri:Area/PubMed/Corpus">001C75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C75</idno><idno type="wicri:Area/PubMed/Curation">001C75</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C75</idno><idno type="wicri:Area/PubMed/Checkpoint">001C75</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001C75</idno><idno type="wicri:Area/Ncbi/Merge">002298</idno><idno type="wicri:Area/Ncbi/Curation">002298</idno><idno type="wicri:Area/Ncbi/Checkpoint">002298</idno><idno type="wicri:doubleKey">0001-6322:1988:Mcgeer P:expression:of:the</idno><idno type="wicri:Area/Main/Merge">005526</idno><idno type="wicri:Area/Main/Curation">004C23</idno><idno type="wicri:Area/Main/Exploration">004C23</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Expression of the histocompatibility glycoprotein HLA-DR in neurological disease</title><author><name sortKey="Mcgeer, P L" sort="Mcgeer, P L" uniqKey="Mcgeer P" first="P. L." last="Mcgeer">P. L. Mcgeer</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, V6T 1W5, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Itagaki, S" sort="Itagaki, S" uniqKey="Itagaki S" first="S." last="Itagaki">S. Itagaki</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, V6T 1W5, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Mcgeer, E G" sort="Mcgeer, E G" uniqKey="Mcgeer E" first="E. G." last="Mcgeer">E. G. Mcgeer</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Kinsmen Laboratory of Neurological Research, Department of Psychiatry, University of British Columbia, 2255 Wesbrook Mall, V6T 1W5, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Neuropathologica</title><title level="j" type="abbrev">Acta Neuropathol</title><idno type="ISSN">0001-6322</idno><idno type="eISSN">1432-0533</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="1988-11-01">1988-11-01</date><biblScope unit="volume">76</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="550">550</biblScope><biblScope unit="page" to="557">557</biblScope></imprint><idno type="ISSN">0001-6322</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6322</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer Disease (immunology)</term><term>Alzheimer Disease (pathology)</term><term>Brain Diseases (immunology)</term><term>Brain Diseases (pathology)</term><term>HLA-DR Antigens (metabolism)</term><term>Humans</term><term>Huntington Disease (immunology)</term><term>Huntington Disease (pathology)</term><term>Immunohistochemistry</term><term>Macrophages (immunology)</term><term>Macrophages (pathology)</term><term>Neuroglia (immunology)</term><term>Neuroglia (pathology)</term><term>Parkinson Disease (immunology)</term><term>Parkinson Disease (pathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>HLA-DR Antigens</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Alzheimer Disease</term><term>Brain Diseases</term><term>Huntington Disease</term><term>Macrophages</term><term>Neuroglia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Alzheimer Disease</term><term>Brain Diseases</term><term>Huntington Disease</term><term>Macrophages</term><term>Neuroglia</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Immunohistochemistry</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: Reactive microglia or macrophages expressing the histocompatibility glycoprotein HLA-DR were detected in many neurological diseases including Alzheimer's, Parkinson's, Pick's and Huntington's diseases, parkinsonism-dementia of Guam, amyotrophic lateral sclerosis, Shy-Drager syndrome, multiple sclerosis and AIDS encephalopathy. Reactive astrocytes, also present in these conditions, were established as a population distinct from the HLA-DR positive microglia by double immunostaining for glial fibrillary acidic protein and HLA-DR. A distinctive pattern of HLA-DR positive cells was seen in each disease entity. Areas known to contain pathology always stained positively, and, in several cases, reactive microglia appeared in areas that would otherwise not have been suspected of being involved in the pathological process. HLA-DR staining, which outlines the surface membranes of positive cells, was so strong that lesioned areas could frequently be identified in sections with the naked eye. In adjacent sections stained with H&E or sections destained of HLA-DR and then restained with H&E, gliosis was often hard to identify except on close microscopic inspection. The results suggest that HLA-DR staining may be a valuable addition to standard neuropathological methods and might be useful in investigating diseases where pathology has not yet been identified.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Mcgeer, P L" sort="Mcgeer, P L" uniqKey="Mcgeer P" first="P. L." last="Mcgeer">P. L. Mcgeer</name></noRegion><name sortKey="Itagaki, S" sort="Itagaki, S" uniqKey="Itagaki S" first="S." last="Itagaki">S. Itagaki</name><name sortKey="Mcgeer, E G" sort="Mcgeer, E G" uniqKey="Mcgeer E" first="E. G." last="Mcgeer">E. G. Mcgeer</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004C23 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004C23 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:253F431DB3D03242FFD77C4693FA3EC8BAA74E22
|texte= Expression of the histocompatibility glycoprotein HLA-DR in neurological disease
}}
| This area was generated with Dilib version V0.6.29. |  |